Format
Items per page
Sort by

Send to:

Choose Destination

Results: 14

Related Articles by Review for PubMed (Select 22479405)

1.

Characterization of the interaction of full-length HIV-1 Vif protein with its key regulator CBFβ and CRL5 E3 ubiquitin ligase components.

Zhou X, Evans SL, Han X, Liu Y, Yu XF.

PLoS One. 2012;7(3):e33495. doi: 10.1371/journal.pone.0033495. Epub 2012 Mar 30.

2.

Structural insights for HIV-1 therapeutic strategies targeting Vif.

Salter JD, Morales GA, Smith HC.

Trends Biochem Sci. 2014 Sep;39(9):373-80. doi: 10.1016/j.tibs.2014.07.001. Epub 2014 Aug 12. Review.

3.

Advances in the structural understanding of Vif proteins.

Barraud P, Paillart JC, Marquet R, Tisné C.

Curr HIV Res. 2008 Mar;6(2):91-9. Review.

4.

Cytidine deaminases as a weapon against retroviruses and a new target for antiviral therapy.

Izumi T, Shirakawa K, Takaori-Kondo A.

Mini Rev Med Chem. 2008 Mar;8(3):231-8. Review.

PMID:
18336343
5.

Structural disorder in the HIV-1 Vif protein and interaction-dependent gain of structure.

Reingewertz TH, Shalev DE, Friedler A.

Protein Pept Lett. 2010 Aug;17(8):988-98. Review.

PMID:
20450485
6.

HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Wissing S, Galloway NL, Greene WC.

Mol Aspects Med. 2010 Oct;31(5):383-97. doi: 10.1016/j.mam.2010.06.001. Epub 2010 Jun 9. Review.

7.

HIV-1 Vif, APOBEC, and intrinsic immunity.

Goila-Gaur R, Strebel K.

Retrovirology. 2008 Jun 24;5:51. doi: 10.1186/1742-4690-5-51. Review.

8.

The role of Vif oligomerization and RNA chaperone activity in HIV-1 replication.

Batisse J, Guerrero S, Bernacchi S, Sleiman D, Gabus C, Darlix JL, Marquet R, Tisné C, Paillart JC.

Virus Res. 2012 Nov;169(2):361-76. doi: 10.1016/j.virusres.2012.06.018. Epub 2012 Jun 21. Review.

PMID:
22728817
9.

[Progress in the study of HIV-1 Vif and related inhibitors].

Li ZY, Zhan P, Liu XY.

Yao Xue Xue Bao. 2010 Jun;45(6):684-93. Review. Chinese.

PMID:
20939174
10.

The role of Vif during HIV-1 infection: interaction with novel host cellular factors.

Lake JA, Carr J, Feng F, Mundy L, Burrell C, Li P.

J Clin Virol. 2003 Feb;26(2):143-52. Review.

PMID:
12600646
11.

Suppression of APOBEC3-mediated restriction of HIV-1 by Vif.

Feng Y, Baig TT, Love RP, Chelico L.

Front Microbiol. 2014 Aug 26;5:450. doi: 10.3389/fmicb.2014.00450. eCollection 2014. Review.

12.

Running loose or getting lost: how HIV-1 counters and capitalizes on APOBEC3-induced mutagenesis through its Vif protein.

Münk C, Jensen BE, Zielonka J, Häussinger D, Kamp C.

Viruses. 2012 Nov 14;4(11):3132-61. doi: 10.3390/v4113132. Review.

13.

Viral infectivity factor: a novel therapeutic strategy to block HIV-1 replication.

Yang G, Xiong X.

Mini Rev Med Chem. 2013 Jun;13(7):1047-55. Review.

PMID:
23621690
14.

Regulation of protein function by 'microProteins'.

Staudt AC, Wenkel S.

EMBO Rep. 2011 Jan;12(1):35-42. doi: 10.1038/embor.2010.196. Epub 2010 Dec 10. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk